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ACC: American college of cardiology 
AHA: American heart association 
CABG: Coronary artery bypass grafting 
CAC: Coronary artery calcium 
CAD: Coronary artery disease 
CTA: Computed tomography angiography 
DM: Diabetes mellitus 
ECG: electrocardiogram 
ESC: European society of cardiology 
EF: Ejection Fraction 
FFR: Fractional flow reserve 
HF: Heart failure 
LV: left ventricular/left ventricle 
LOE: Level of evidence 
MBF: Myocardial blood flow 
MI: Myocardial infarction 
MPI: myocardial perfusion imaging 
MRI: Magnetic resonance imaging 
MFR: Myocardial flow reserve 
PCI: percutaneous coronary artery intervention 
PET: positron emission tomography 
PROMISE: Prospective multicenter imaging study for evaluation of chest pain 
RV: Right ventricular/right ventricle 
SPECT: single photon emission tomography 
SSS: Summed stress score 
SRS: Summed rest score 
SDS: summed difference score 
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Summary 
As the second term of our commitment to Journal begins we, the editor, would like to reflect on a 
few topics that have relevance today. These include: prognostication and paradigm shifts, Serial testing: 
How to handle data?  Is the change in perfusion predictive of outcome and which one? Ischemia guided 
therapy: fractional flow reserve vs. perfusion vs. myocardial blood flow; positron emission tomography 
(PET) imaging using Rubidium-82 vs. N-13 ammonia vs. F-18 Flurpiridaz; How to differentiate 
microvascular disease from 3-vessel disease by PET? The imaging scene outside the United States,  what 
are the differences and similarities?  Radiation exposure; Special issues with the new cameras? Is 
attenuation correction needed? Are there normal databases and are these specific to each camera 
system? And finally, hybrid imaging with single photon emission tomography or PET combined with 
computed tomography angiography or coronary calcium score. We hope these topics are of interest to our 
readers. 
In 2014, we published an inaugural paper listing some of the themes and challenges in nuclear 
cardiology (1). Table 1 is a summary of the topics addressed in that paper. In the interim, the Journal of 
Nuclear Cardiology has published numerous papers dealing with these and many more issues and for that 
we are very pleased.  While many of these topics have been addressed, few, [such as how do we integrate 
nuclear and nonnuclear data in guiding patient management on a personalized basis? (Items #6) and ‘what 
is the model nuclear cardiology laboratory in the next decade?” (Item #15)] need more work and input. We 
believe our reports could be more a bit more comprehensive, reader-friendly, and personalized and the 
configuration of nuclear labs in the future may vary depending on resources and needs and there may 
differences between academic institutions and out- patient imaging facilities. 
The journal has published several papers on the expanding use of nuclear cardiology in non-
ischemic heart diseases such as sarcoid and amyloid heart diseases, infections of native valves, prosthetic 
valves and pacemaker or defibrillator leads and pockets and neuro-imaging to mention few. 
As the Journal begins a second term under same editorship, we thought to present the second 
inaugural paper in which we identify a new set of challenges. Much has been written about these topics but 
our goal is to provide a broad perspective based on the experience and knowledge of our seasoned 
editors. 
We think to move forwards we need to learn from our past, both success stories and failures. More 
on this could be found in the Editor’s page in this issue, Amongst the many Nobel laureates in our field, are 
Marie Curie (MC) and her husband Pierre Curie. Every practitioner should know of them, since Ci and mCi 
are commonly used measurements in the field of nuclear medicine. Ironically, MC turned down the first 
marriage proposal by Pierre but accepted his second, in which he wrote” it would be a beautiful thing, a 
thing I dare not hope, if we could spend our life near each other hypnotized by our dream: your patriotic 
dream, our humanitarian dream and our scientific dream”; so sweet. MC won 2 Nobel prizes 
Seventy years after MC won the first of two Nobel Prizes, a seminal paper on myocardial perfusion 
imaging (MPI) was published in the New England Journal of Medicine (2). Of note, the summary (abstract) 
of this paper was not structured; there were only 43 patients (15 of them had rest studies only);  the MPI 
was done using planar imaging with a radionuclide that is no longer in clinical use, and there were only 
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simple statistical analyses! The authors of this paper were from the Travis Airforce Base. Yet this paper 
changed the careers of many of us.  
In 2017, the Journal established a committee to identify and acknowledge individuals who had or 
those who continue to provide meaningful contributions in our field (3)  
Prognostication and paradigm shifts:  
The use of MPI has changed over time from establishing diagnosis of coronary artery disease 
(CAD) to risk assessment and decision making for appropriate treatment strategies.  Prediction of patient 
outcome has also changed over time from short-term outcome (warranty period) to long-term outcome. 
Outcome has been defined as death (sudden death, cardiac death, and all -cause mortality); non-fatal 
myocardial infarction (MI); heart failure (HF) or HF exacerbation, the need for hospitalization; unstable 
angina, the need for coronary angiography or revascularization, quality of life or change in medications. As 
the bar was raised up further, new items became even more important such as ability to alter outcome 
using MPI, the need to demonstrate value (value =outcome achieved relative to cost), Could the risk be 
modified? How? Is risk modification predictable by changes using serial imaging? (4) 
Figure 1 shows images from 2 patients, one with a reversible defect (ischemia) and one with a 
persistent (fixed) defect of comparable size and distribution. The summed stress score (SSS) is similar in 
the 2 patients but not the sunned difference score (SDS) and summed rest score (SRS). These images 
raise several issues in terms of assessing diagnosis and prognosis. First, should patients with prior MI (and 
fixed defects) be included in assessing diagnostic accuracy of MPI? One can argue this point both ways, 
because surely fixed defects are indicative of CAD (in most patients) but it also inflates sensitivity. But the 
bigger question is “which of the prognostic endpoints is most applicable to the two patients”? Often, the 2 
patients are lumped together but the question should we couple image findings to specific outcome (s)? 
Intuitively, one would think that the likely events in the first patient are myocardial infarction, unstable 
angina or death while in the second patient are HF or death This issue is not unique to MPI but apply to all 
imaging modalities.  
Figure 2 shows serial images on a patient with CAD and angina pectoris. At baseline, there is a 
moderate sized stress-induced perfusion defect. After medical therapy, symptoms improved and there was 
a decrease in perfusion defect size (reversible defect). When therapy was discontinued, the symptoms 
worsened and there was an associated increase in defect size to pretreatment level. So far so good but 
interestingly, the level exercise, as defined by METS and peak heart rate, were identical on all 3 occasions. 
So, the question is which endpoint is most useful in this patient? Did changes in perfusion defect explain 
the symptomatic improvement? Is it possible that the perfusion abnormality occurred early during exercise 
before treatment (silent ischemia) but late during exercise after treatment? These questions also highlight 
the difficulty in translating data derived from a large cohort of patients to individual patient. Finally, in the 
current era of cost containment was serial imaging in this patient cost-effective? 
There is also a paradigm shift in imaging because CAD mortality rates have decreased by 70% in 
the past 20 years, MI is less frequent and less severe, there is a decline in frequency of inducible ischemia 
by stress SPECT MPI, the notion that MPI underestimates extent of CAD and has limited ability to detect 
subclinical atherosclerosis, the shift in nuclear imaging from being a revenue center to being a cost center, 
and increasing competition from other imaging modalities. These changes have resulted in examining the 
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need of alternative methods such as the coronary calcium scoring in asymptomatic patients and hybrid 
imaging in symptomatic patients (see below) (5). 
 
Serial testing: How to handle data?  Is the change predictive of outcome and which one?  
There are several issues with serial testing. For simplicity, we will focus on MPI. When is it 
indicated?  How is it performed and analyzed?  How reproducible are the results so that serial changes can 
be accurately assessed? Each one of these issues deserve a full review, and some of it has been 
discussed previously (1). There are few observations worth noting; First, none of the guidelines and 
appropriateness criteria refer to the need or recommend serial imaging; one would think that there are 
subgroups of patients where this might be useful, such as patients with silent ischemia, patients with a 
large area of ischemia who are treated medically, or those with persistent symptoms despite undergoing 
successful coronary artery revascularization to mention a few. Second, despite 4 decades of using MPI and 
thousands of publications, the number of papers on serial imaging is small. This may have different 
reasons but one that comes to mind is the difficulty of how to analyze the data?  
Two recent papers, one on coronary calcium scoring and one on troponin, addressed serial 
imaging (6, 7). The calcium paper found that the final calcium score but not the change in calcium score 
from the first to the second study, to be the most important marker of outcome (6). On the other hand, the 
troponin paper found the change to be the important marker (7). The question is why? Is it because 
troponin measurements are more reproducible than calcium score measurements or because an increase 
in coronary calcium may represent plaque healing? 
With MPI, the problem is even greater as the options in interpretation are more diverse: initial vs. 
follow-up vs. changes in SSS, SDS and SRS. Keep in mind that worsening in one vascular territory and 
improvement in another could result in no net change! That may be true even when the analysis is 
performed on a regional rather than global level 
This observation raises the question of what is the ideal method of analysis? Surely “supervised” 
automated analysis is preferred over visual analysis because of a better reproducibility, but the 
conventional method of automated analysis involves comparing each set of images (initial and follow-up) to 
a normal database. Recently a method has been described where multiple images from the same patient 
are compared to each other rather than to a database, which is appealing and deserves to be tested in 
future studies because smaller or milder differences might be more readily detected (8). 
The use of serial MPI is inherently more difficult than serial radionuclide angiography where the LV 
ejection fraction (EF) is the measurement of interest. There are data on serial testing using phase analysis 
and neuro-imaging but the settings in which serial testing provides value using these methods need to be 
addressed (9,10). 
Ischemia guided therapy: fractional flow reserve vs. perfusion vs. MBF  
Stress-induced (exercise or pharmacologic) reversible myocardial perfusion defects have been 
firmly established to reflect myocardial ischemia in a vascular territory that is often subtended by a flow-
limiting epicardial coronary artery stenosis (11).  These MPI studies are interpreted primarily by assessing 
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regional perfusion defects in relative terms, qualitatively or semi-quantitatively.  Physiological studies of the 
coronary circulation and regulation of myocardial blood flow (MBF) are optimally performed with 
measurements of absolute MBF (mL·min−1·g−1) (12).  Several retrospective prognostic studies have 
reported on the incremental prognostic value of absolute MBF and flow reserve with positron emission 
tomography (PET) compared to the conventional relative radiotracer uptake. An important driver for cardiac 
PET in this direction comes from recent trials which have suggested that physiological indices are superior 
to anatomical ones for guiding therapy and improving outcomes in CAD patients (13). Unlike so many 
facets of modern cardiovascular practice and CAD management, where absolute values of key parameters 
and indices are measured, absolute rest and maximal MBF have yet to be incorporated into routine clinical 
practice (12-15). There are numerous reports of absolute PET MBF measurements identifying multi-vessel 
CAD that were missed when images were interpreted in terms of relative radiotracer uptake (16).  However, 
systematic comparison of absolute PET MBF measurements with SPECT MPI for the diagnosis of CAD 
has not been reported. 
Recent efforts in the interventional laboratory have focused on coronary pressure–based 
measurements such as fractional flow reserve (FFR) to assess maximal coronary vasodilator capacity and 
flow reserve as indicators of coronary stenosis severity and microvascular function. FFR is an invasive 
measurement of the coronary circulation and has gained wide acceptance as a decision-making tool for 
coronary revascularization because it is an excellent predictor of clinical outcomes (17).  Non-invasive 
measurements of absolute MBF with PET are equally suited for determining the physiologic significance of 
CAD with the advantage of preventing unnecessary cardiac catheterization in patients who may not benefit 
from revascularization. In one report, applying rubidium-82 PET, the threshold of stress MBF <0.91 
mL·min−1·g−1 was shown to be highly predictive of the occurrence of severe myocardial ischemia (16).  In 
contrast, evidence of severe ischemia was rarely encountered when the stress MBF was >1.12 mL·min−1. 
Studies comparing MBF by PET to FFR have shown only modest correlation between FFR and 
coronary flow reserve ratio (CFR, stress/rest MBF) because of the divergence of peak MBF from FFR in the 
range from 0.7 to 1.0, due to presence or absence of diffuse and/or microvascular disease. A much 
stronger correlation with relative flow reserve (stress flow in culprit zone/rest flow in culprit zone divided by 
stress flow in control zone/rest flow in control zone) has been reported (18). The correlation of relative flow 
reserve with FFR likely reflects the fact that FFR had initially been validated against stress induced defects 
on MPI.  
Accordingly, it has been hypothesized that patients manifesting ischemia with pharmacologic 
vasodilator stress in whom MBF cannot be increased >0.91 mL·min−1·g−1 may be at high risk for 
cardiovascular death or MI and would benefit most from coronary revascularization (16).  While these 
thresholds need to be tested and verified in multicenter clinical trials, it is important to keep in mind that 
decisions about the need for cardiac catheterization and coronary revascularization must be individualized 
and cannot be made solely on a single stress MBF or flow reserve value. Moreover, there will be individual 
variations in MBF required to achieve a given level of external work that is free of myocardial ischemia (19).  
A desirable change in nuclear cardiology is to bring noninvasive absolute PET MBF measurements in line 
with coronary interventional practice, which is increasingly focused on objective, functional parameters of 
CAD severity, to guide management of myocardial ischemia and to predict and improve patient outcomes 
(12, 20). 
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PET imaging. Rubidium-82 vs. N-13 ammonia vs. F-18 Flurpiridaz 
Currently N-13 ammonia and rubidium-82 (Rb-82) are approved by the Food and Drug 
Administration in the Unites States for assessing myocardial perfusion and MBF. Oxygen-15 water is also 
used, but less frequently. F-18 Flurpiridaz is undergoing clinical trials with the hope of future approval. 
F-18 Flurpiridaz has a longer half-life than N-13 ammonia and Rubidum-82 (109 min vs. 9.96 min 
vs 1.25 min, respectively) and requires a regional cyclotron for its production rather than an on-site 
cyclotron (N-13 ammonia) or generator (Rubidium-82). Further, the positron range of F-18 Flurpiridaz is 
shorter than that of N-13 ammonia and Rubdium-82 (1.03 vs 2.53 vs. 8.6 mm, respectively), which means a 
higher spatial resolution of the perfusion images. Also, the initial extraction fraction is higher than N-13 
ammonia and Rubidium-82 and closer to Oxygen-15 water even at high rates of MBF. The longer half-life 
of F-18 enables the use of F-18 Flurpiridaz in virtually all centers that provide PET scanning, without the 
need for sufficient volume of studies to support a Rubdium-82 generator or the proximity to a cyclotron that 
is needed with N-13 ammonia. Finally, the longer half-life of F-18 allows for exercise testing, which is less 
practical with N-13 ammonia and not practical with Rubdium-82. Flurpiridaz is associated with somewhat 
higher though still low radiation (21, 22). 
How to differentiate microvascular disease from 3-vessel disease by PET-MBF? 
The diagnostic and prognostic value of flow and flow reserve measured using dynamic cardiac 
PET perfusion imaging is now well established (11, 19, 20, 23-31) and presents the advantage for 
excluding balanced ischemia due to 3-vessel CAD. (19, 20, 23-31,)  ASNC guidelines note that 
quantification of MBF using PET appears to be most useful in the following circumstances (11): “1) patients 
without a known  history of CAD who present with symptoms suspect for myocardial ischemia; 2) patients 
with known CAD, in whom more specific physiological assessment is desired; 3) Identifying [patients with] 
an increased suspicion for multi-vessel CAD; 4) to assess possible microvascular dysfunction; 5) heart 
transplant patients when there is a question of transplant vasculopathy”. 
However, how to distinguish whether impaired flow and flow reserve are due to obstructive CAD 
versus flow impairments due to endothelial and/or microvascular dysfunction versus varying combinations 
of both is not easy and, strictly speaking, is not possible when flow measurements are considered in 
isolation. As such, flow data interpretation must always be considered in context and in conjunction with all 
available information including history (symptoms, coronary risk factors, known CAD), ECG changes, 
coronary calcium score, perfusion imaging findings, left ventricular (LV) size and function, right ventricular 
(RV) uptake and transient ischemic dilation (TID) (20, 23 ). 
Is there a cut-off value that predicts obstructive CAD?  No; and there are variations in cut-offs for 
what is defined as normal that vary with different tracers, different analysis software, age, and diffuseness 
of disease. In general, a global MFR (Myocardial Flow Reserve) ≥2.3 (without regional variability) with 
virtually all PET perfusion tracers indicates a good prognosis (11, 20). Cut-off values for Rubidium-82 and 
N-13 ammonia have been reported as ≥2.0 (27, 28). When flow reserve is above these cut-points, the 
likelihood of significant obstructive multi-vessel CAD or microvascular disease is lower.   
It has been shown that as global MFR decreases, the likelihood of obstructive CAD increases 
progressively. In one study, the point estimates for the likelihood of 3-vessel obstructive CAD for MFR 
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values of <2.0, <1.5 and <1.0 were 11%, 25% and 48% respectively. The sensitivities and specificities for 
MFR cutoff values of <2.0, <1.5 and <1.0 were 88 and 51%; 80 and 74%; and 36 and 96%, respectively, for 
balanced 3-vessel obstructive CAD (27).  But these sensitivity and specificity values would indicate that this 
is not an absolute diagnosis. Accordingly, other information is needed.  Any history of known CAD, the 
presence of coronary calcification and/or regional reductions in flow, point more to indicate obstructive 
CAD.  Their absence points more to microvascular disease. Of note, patients may also have combinations 
of obstructive CAD in 1, 2 or 3 vessels and diffuse atherosclerosis and/or microvascular disease impairing 
global flow.  
To complicate matters further, reduced absolute hyperemic myocardial blood flow and flow reserve 
with pharmacological vasodilator stress can be due to:  multi-vessel obstructive CAD; diffuse 
atherosclerosis; endothelial dysfunction or microvascular disease; combinations of these; but can also be 
due to insufficient response to the vasodilator stress (due to caffeine intake or patient specific variances).  
So-called non-responsiveness should be suspected if global and regional MFR are uniform and at/or about 
1.0 with little or no hemodynamic change and no other findings to suggest severe ischemia (i.e., no ECG 
changes, no change in perfusion, no TID).  In such circumstances, the stress portion of the test may need 
to be repeated either ensuring no caffeine intake, extending the period of caffeine abstinence, or using 
another pharmacologic stress imaging agent (20, 23). 
Recent data from small cohorts of patients with CAD have observed that longitudinal flow gradients 
(measured as the change in flow from the mid to the mid-distal segments of the LV) is correlated to FFR 
(30) Also, the change in longitudinal flow gradients between stress vs rest (particularly when combined with 
MFR) provides an accurate means to identify obstructive CAD (31). These data suggest that longitudinal 
flow gradients may optimize identification of obstructive CAD in the presence of multi-vessel CAD. Others 
have also examined relative flow reserve (essentially regional stress flow/maximal stress flow) 
demonstrating that global stress flow identifies well diffuse atherosclerosis while relative flow reserve better 
identifies significant stenoses. Future studies in patients with microvascular disease are needed to 
determine if these parameters can truly optimize the distinction of microvascular, endothelial, and diffuse 
atherosclerotic disease from 3-vessel obstructive CAD or determine their relative importance and 
contribution to the patient’s symptoms or prognosis. 
Ultimately integrated structure-function information is required to make the definitive diagnostic 
distinction between microvascular disease and 3-vessel CAD or define their relative contribution in each 
patient’s coronary vascular disease. Certainly, when global or regional flow reserve is below 1.5 (or 1.7 
depending on software and lab), defining anatomy is recommended given the increased risk for these 
patients (11, 19, 20, 23, 26, 28, 29). 
While MBF and MFR have enabled greater ability to detect multi-vessel disease and microvascular 
disease, there remain challenges in wide spread use of MBF and MFR measurements.  Some of these 
include standardizing measurements between sites and educating ourselves and referring physicians 
regarding the added clinical value and how to interpret the added flow reserve data with or without multi-
vessel CAD. More prospective multicenter studies are needed to expand our understanding of:  the role 
and importance of microvascular disease and its treatment; the full clinical value of MFR and MBF; and the 
role of MBF and MFR measurements in selecting and monitoring therapies. 
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The scene outside USA: what are the differences and similarities?   
 The local practices of imaging in general and nuclear imaging is quite variable outside the United 
States. (32, 33) Just for example there are more than 30 nations involved in the writings of the European 
Society of Cardiology (ESC) guidelines. In many places in Europe, advanced imaging using state-of-the-art 
technology including PET is available in academic centers. What is interesting, however, are the subtle 
differences between ESC and American College of cardiology/American Heart Association (ACC/AHA) 
guidelines. There is a stronger argument for hybrid imaging in ischemic and non-ischemic cardiac diseases 
in the ESC guidelines and more emphasis on non-imaging treadmill exercise testing in the ACC/AHA 
guidelines in ischemic heart diseases (Table 2) (34, 35). These differences might disappear in future 
updates of these guidelines. Parenthetically, almost ½ of the submissions to our Journal come from outside 
the United States and our composition of editors, Board members and publication committee clearly reflect 
this International collaboration. 
Radiation exposure  
The entire field of nuclear cardiology is predicated on the application of a radioactive tracer 
technique in combination with sophisticated electronic nuclear instruments to image a highly specific signal 
with superior contrast resolution that allows the differentiation between normal and abnormal myocardial 
perfusion, metabolism, or innervation. That there is radiation exposure from nuclear imaging has never 
been disputed, given the fundamental basis of using low doses of radioactive tracers to gain insight into 
normal and abnormal cardiovascular physiology and disease processes.  The concept of applying the 
ALARA (as low as reasonably achievable) principle is to inject the lowest radiotracer dose possible that 
allows the acquisition of high quality images which can be interpreted reliably without sacrificing diagnostic 
accuracy (36-38). 
The calculation of radiation risk is imprecise and it represents extrapolated estimated risk from 
epidemiologic data to the clinical setting (36). As such, there is an ongoing debate regarding the true 
incremental risk to subjects exposed to low doses currently administered in cardiovascular procedures.  
There is uncertainty of the dose-response relationship in this lower diagnostic range radiation doses, as 
well as tissue-specific reparative responses.  Given the uncertainty, any ability to reduce radiation by any 
amount would be a positive advancement and consistent with the principle of ALARA.  A study by the IAEA 
(International Atomic Energy Agency) has documented regional variations world-wide (37). There are many 
ways to lower the radiation exposure including the use of stress- only imaging when applicable, newer 
SPECT hard-wares and soft wares, PET imaging, and more importantly appropriate utilization. A recent 
paper provided a thorough analysis and modeling of the radiation risks (38).  It is understood that no 
discussion on risk is complete without acknowledging the tremendous contributions of nuclear cardiology 
imaging to patient management which explains why despite all new developments it remains the most 
popular non-invasive stress test. 
Special issues with the new cameras? Is attenuation correction needed? Are there normal 
databases and are these specific to each camera system?  
The initial reports on the a truly revolutionary change in the design of SPECT detectors to use 
cardiac-centric solid-state detectors with pinhole (39, 40) or parallel-hole collimators have been followed 
with research reports confirming their value. In addition to using new detectors and/or new collimators, the 
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general concept is to image the LV in the center of the field of view to allow more but smaller detectors or 
magnification of the LV image in the crystal to significantly increase count sensitivity (41). Compared to 
conventional SPECT, these new systems together with newer reconstruction software that incorporates 
resolution recovery, noise modeling, with or without attenuation correction yield images with higher contrast 
and spatial resolution, acquired in shorter time and/or with reduced radiation doses to the patient (42). This 
advancement in instrumentation and software yields SPECT studies with higher image quality, reduced 
radiation, and increased efficiency. Similarly, quantification of global and regional LV function has been 
shown to correlate well (43) with conventional devices even when using lower doses and faster acquisition 
times with the new cardio-centric devices (44, 45). These benefits do come at a higher cost compared to 
conventional dual head parallel-hole SPECT systems and may be a lower specificity, though this was noted 
in the early experience (46). 
These cardio-centric cameras require centering the LV in the center of a somewhat reduced field of 
view for optimal results (47). Moreover, for accurate relative perfusion quantification, the higher image 
contrast resolution of these new cardio-centric systems requires the use of myocardial perfusion normal 
databases specific to the device or at least from a general class of higher contrast resolution images (42, 
48). Just like with standard SPECT cameras, two position imaging (supine/prone or upright/supine) 
increases the specificity of detecting patients with evidence of myocardial hypo-perfusion, compared to one 
position imaging (49). When available, attenuation correction has the advantage that it works in concert 
with the higher energy resolution of the solid-state detectors and the resolution recovery and noise 
modeling reconstruction to yield more accurate voxel values than two position imaging, and has the 
potential to provide absolute radiotracer concentrations. Preliminary data suggest feasibility of flow 
quantification with existing tracers. 
Hybrid SPECT/CT and PET/CT 
Hybrid PET/CT or SPECT/CT systems permit simultaneous coronary anatomic and physiologic 
radionuclide assessment in a single study. Most PET scanners currently used for MPI are hybrid PET/CT 
systems which can perform CT assessment of coronary anatomy. SPECT/CT systems are also available, 
but currently make up only a small fraction of the equipment used for SPECT-MPI. The hybrid systems can 
evaluate the presence and magnitude of CAD using coronary artery calcification (CAC) or coronary CT 
angiography (CCTA) (50, 51) 
A highly effective and practical application of hybrid PET-SPECT/CT systems is the performance of 
MPI and CAC scanning in a single setting. CAC provides essentially a “no cost” add on to MPI and is 
performed with minimal additional radiation to the patient. This combination is complementary to MPI in four 
important ways.  
First, a limitation of stress MPI, whether performed with PET or SPECT, is that regional stress 
perfusion abnormalities are inducible only in coronary arteries with hemodynamically significant lesions. 
This approach fails to identify patients with subclinical atherosclerosis in whom aggressive medical and 
lifestyle modification might prevent subsequent cardiac events. Most patients undergoing MPI have normal 
examinations (52), and when they are normal, the test results often do not alter patient management. The 
degree to which this occurs limits the potential of the MPI studies to provide value in our increasingly cost-
conscious era. CAC provides a marker of the extent of calcified coronary atherosclerosis in an individual 
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patient, overcoming the limitations of population-based global risk scores. By affording the simultaneous 
assessment of the presence of coronary atherosclerosis as well as of myocardial ischemia, the finding of 
an abnormal scan can lead to beneficial changes in therapy and greater patient compliance with 
therapeutic recommendations (53). 
Second, the addition of CAC scanning to MPI improves risk stratification.  The presence of CAC 
and MPI abnormality is synergistic with event rate rising with each increment of abnormal CAC scan 
categorization (54). While SPECT MPI assessment of ischemia is an excellent test of short-term prognosis, 
CAC scanning provides better discrimination of long-term risk, due to its assessment of non-obstructive 
CAD. More than a decade ago, it was recognized that high CAC scores are common in patients with 
normal SPECT MPI (55). The short-term risk was found to be low in such patients (52); however, 
subsequent longer-term follow-up demonstrated substantial risk of cardiac events (54, 58).  The extent of 
CAC also improves risk assessment of patients with abnormal MPI examinations (54, 58).  
Third, the combination of CAC with MPI can also lead to increased certainty in scan interpretation 
and accuracy in detection of hemodynamically significant stenosis. This benefit is particularly useful when 
faced with borderline MPI abnormalities or when there is discordance between the nuclear MPI results and 
clinical or ECG responses to stress (55).  
Fourth, the extent of CAC abnormality provides a more accurate assessment of the likelihood of 
obstructive CAD than consideration of age, sex, and risk factors in asymptomatic patients (59). When CAC 
is absent, the likelihood of CAD is generally low. In this circumstance, borderline findings or discordant MPI 
results can be weighed toward normal in reporting and in treatment recommendations. Extensive CAC 
indicates an intermediate to high likelihood of obstructive CAD. When found in a patient with borderline or 
discordant MPI findings, extensive CAC can be useful in raising the possibility not only of the presence of 
obstructive CAD but of the potential of high risk CAD (60).  
Which patients would benefit from hybrid imaging with combination of CAC with MPI? The above 
considerations would suggest that it may be all patients without known CAD. 
Coronary CTA can also be performed during the MPI examination using recent generation PET/CT 
systems that have minimum of 64 detector rows and rotation time to produce adequate CTA studies. 
Sequential testing, MPI followed by CTA in selective patients with documentation of inducible ischemia is 
also an option. Due to the ability to define the presence, location, and degree of coronary stenosis, CCTA 
can be more definitive than CAC scanning in guiding management of patients with borderline or discordant 
MPI results as well as in further assessment of the need for invasive angiography patients with mild 
degrees of ischemia. The combination of testing essentially eliminates a well-described problem of relative 
perfusion defect assessment of MPI—the potential failure to identify patients with high risk CAD due to 
balanced reduction in coronary blood flow (61). To a degree, this problem is averted with PET MPI, as 
noted above, by addition of absolute quantitation of myocardial perfusion (62); however, also as noted, 
diffuse reduction of flow reserve, a marker of increased risk, can be seen not only in patients with extensive 
ischemia from epicardial CAD but also in the presence of microvascular disease. When diffuse flow 
reduction is observed by PET, further anatomic assessment for this clinically important distinction often 
becomes necessary. 
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Studies have evaluated hybrid PET-MPI/CTA, with both studies performed in the same setting, with 
respect to prediction of hemodynamically significant stenosis defined by invasive angiography in 
combination with FFR (24, 63). These studies have demonstrated higher accuracy of the combination than 
with either modality alone. However, because it is difficult to predict in advance whether a patient will need 
both studies, the practicality and cost-effectiveness of the routine combination of the two studies is 
questionable. If a single test provides sufficient information to accurately guide patient management, the 
routine performance of both tests would have resulted in unnecessary costs and radiation. Current opinion 
is that this routine coupling of MPI with CCTA is not likely to become routine.  
Coronary CTA is increasingly being used as the initial test in patients with suspected CAD. 
However, it is important to point out that anatomic-based CT strategy identifies a significant number of 
patients with indeterminate coronary CTA lesions (between 30% and 70%) requiring additional physiologic-
based imaging studies (accruing additional cost and radiation risk). On the other hand, an abnormal initial 
physiologic-based study (SPECT or PET) would direct the patient to coronary angiography for both 
diagnostic confirmation of the coronary artery lesion and therapeutic intervention during the same 
encounter averting unnecessary radiation and contrast from a diagnostic coronary CTA. 
 Advantages of coronary CTA over a standard of care approach that included stress testing was 
suggested by the SCOT-Heart trial (63, 64). In that trial, a substantial change in preventive therapies in the 
CCTA arm was noted and likely played a significant role in the trial findings. In the PROMISE trial, which 
compared coronary CTA to stress testing, there was an increase in statin and aspirin use in coronary CTA 
arm as well as improved lifestyle behavior. If CAC scanning had been performed along with stress testing, 
the use of preventive therapies may have been similar. Potentially, routine coupling of CAC scanning with 
SPECT- or PET-MPI by hybrid scanning, by providing the assessment of coronary atherosclerosis, could 
allow MPI to be more competitive with coronary CTA. This important consideration as to how hybrid 
CAC/PET or SPECT MPI would fare regarding “value” when compared to CTA has not been studied and 
would be of great interest. Several molecular imaging techniques are now in the clinic and others are used 
as companion for clinical trials and drug development. Many more techniques are in the pipeline. 
Training and the imager of the future  
Rapid technological developments in echocardiography, nuclear cardiology, cardiac computed 
tomography (CCT) and cardiac magnetic resonance (CMR), and the expanded applications of these 
technologies to the patient with cardiovascular disease, has necessitated a rethinking of the definition and 
training requirements of the cardiac imaging specialist. Competing considerations influence this prevalent 
debate, and have resulted in conflicting opinions: the silo approach, of an imager with expertise in a single 
modality, to the “multi-modality” imager who has expertise in multiple or “all” modalities.  The report of a 
recent think-tank convened by the American College of Cardiology, and the accompanying editorial by the 
editors of JACC Cardiovascular imaging capture the essence of this debate (65, 66).  
The required exposure for a trainee within the finite three-year period of a cardiovascular fellowship 
has expanded considerably, making it difficult to acquire expert level training in multiple imaging modalities 
without additional training time. Furthermore, the maintenance of a high level of expertise and sustaining 
credentialing requirements in multiple modalities throughout the course of one’s career is difficult. So, can 
the cardiac imaging subspecialist truly be a multi-modality expert, or should the definition be based on a 
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career path dedicated to imaging, with high level of expertise in one or two modalities combined with a 
broad exposure to other modalities?(66)  In this debate, consideration must also be given to the vast array 
of non-traditional, web-based resources now available to the trainee that make it less time- intensive to 
acquire a broad exposure to multiple modalities and to maintain competence during clinical practice (67). 
Training decisions are heavily influenced by practice setting requirements. The community setting 
with fewer practitioners favors a multimodality imager and this approach may protect against layered or 
duplicative testing and overuse of imaging.  In an academic setting, individual practitioners working 
together, each with high-level expertise in one or two modalities may create a multimodality service.  
Ultimately, skill sets and thus training, will need to be adapted based on the practice setting 
(academic or community) and career path (interpretive skills versus a leadership role in an imaging 
laboratory or research). However, adapting training curricula to individual and market needs is distinct from 
our quest to optimally define the designation of an advanced cardiac imaging expert. Not everyone who 
provides interpretive service will qualify for that designation. For the latter, our criteria should be rigorous if 
we are to maintain our identity as a credible subspecialty. 
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Table 1:   Myocardial perfusion imaging: Lessons learned and work to be done (from ref 1)                                                         
1- Physiology of the coronary circulation as a building block to perfusion imaging 
2- Are the data on sensitivity and specificity valid knowing that severity of stenosis on coronary 
angiography does not predict flow or fractional flow reserve (FFR)? What is the current role of FFR? 
3- Can we have new recommendations on doses and sequences of imaging and stress imaging only? 
4- Why is attenuation correction not widely used? 
a.  Have the newer software programs eliminated the need for attenuation correction? 
b. Does early imaging with the newer cameras decrease sub-diaphragmatic activity and the need for 
attenuation correction?  
c. What is the current processing algorithm of choice? 
5- Is hybrid stress testing underused or overused? Are there special populations that have yet to be 
addressed? 
6- How do we integrate nuclear and nonnuclear data into personalized medicine in guiding patient 
management? 
7- Should the newer cameras replace the conventional ones or are there still unanswered questions? 
8- What is the interaction between scar and ischemia with left ventricular (LV) ejection fraction (EF) 
and volumes? 
9- How does one compare summed rest score (SRS), summed stress score (SSS), and summed 
difference score (SDS) by visual or automated method and polar maps-derived indices from one 
commercial software to another?  
10-  Are predictors of sudden death comparable to those predicting death of any cause or cardiac 
death? 
11- Is viability testing clinically useful and how should this data be used in clinical decision-making? 
12- What about non-perfusion variables? 
13- Do statistical analyses correct or create problems? Do advanced statistical methods open novel 
domains in the study of nuclear cardiology? 
14- How far is cardiovascular molecular imaging from mainstream clinical use? 
15- What is a model nuclear cardiology laboratory in the next decade? Will it include SPECT or PET or 
both and in what degree? 
16- Does artificial intelligence have a role in the modern nuclear cardiology laboratory? 
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Table 2: Comparison between ESC and ACC/AHA guidelines in CAD 
  ESC ACC/AHA 
Detection of CAD <15% probability IIIA-stress MPI and echo IIIC-stress MPI, echo, MRI if 
rest ECG is interpretable
  IIIC-Stress MRI, PET, 
Hybrid, CTA 
 
 15-85% probability A-stress MPI, MRI, PET IA-TET 
  IIA- CTA IB-exercise MPI or echo if 
ECG is interpretable 
  IIB-hybrid imaging IB-Pharm MPI or echo if 
patient cannot exercise 
   IIA-CTA (LOE B) 
   IIB-CAC (LOEC) 
 >85% probability IA-invasive angiography IA-invasive angiography 
    
CR DM IIA-PCI for syntax score 
<22 (LOE B)o 
IA-CABG 
 No DM New generation stents as 
default in all patients 
Bare metal stents for high 
bleeding risk, inability to 
comply with DAPT >12 
months, anticipated non-
cardiac surgery <12 months
 
-After CR DM Imaging is preferred over 
TET for new or worsening 
symptoms 
TET or imaging for new or 
worsening symptoms 
  For asymptomatic, IIC >2 
years for PCI and >5 years 
for CABG 
For asymptomatic, IIA-prior 
silent ischemia, high risk 
patients or incomplete CR 
(LOE C) 
Abbreviation 
PET: Positron emission tomography, CTA: computed tomography angiography, MRI: Magnetic resonance 
imaging, TET: treadmill exercise testing, CAC: coronary artery calcium, CAD: Coronary artery disease, 
ESC: European congress of cardiology, ACC: American college of cardiology, AHA: American heart 
association MPI: Myocardial perfusion imaging, DM: diabetes mellites, PG: Coronary artery bypass 
grafting, DAPT: dual antiplatelet therapy, LOE: level of evidence, CR: coronary revascularization 
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Legends –  
Figure 1: Single photon emission tomographic (SPECT) myocardial perfusion images (MPI) (post stress 
and rest) showing a large reversible abnormality in the left panel and a large fixed abnormality in the right 
panel 
Figure 2: Polar maps from stress/rest SPECT MPI obtained from the one patient. Top panel: before medical 
treatment; middle panel: after treatment and lower panel: after discontinuation of treatment. The patient 
exercised to the same heart rate and achieved similar METS at all 3 examinations. Though the perfusion 
abnormality decreased after treatment, there was no change in exercise time but the patient felt 
subjectively improved. He felt worse after discontinuation of treatment with the larger perfusion defect.  
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